Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Development Tools === InSight Development Kits provide the hardware and software tools needed for application development. InSight Desktop allows for the programming and debugging of applications. It combines a packet sniffer, network analysis features, API tracing, and a virtual UART. InSight Adapter is used for network and microprocessor debugging and for programming chips. InSight USB Link is a FLASH programming device that connects to any PC via USB and to Ember’s Radio Control Module (RCM). It contains the hardware and software tools that read and write applications and program FLASH memory on the chips. AppBuilder makes network customization possible. It generates a template application that allows developers to tailor the EmberZNet PRO software to their specifications and complete the application, readying it for hardware integration and testing. It also allows configuration of the Hardware Abstraction Layer (HAL) and generates source code application with places for the developer to insert their own OEM-specific code. xIDE is a tool-chain that supports applications being written for the EM250. It has a C-language compiler, assembler, source-level debugger, and graphical editing environment.
In (1) the ethylenediamine forms a chelate complex with the cadmium ion. Chelation results in the formation of a five-membered CdC2N2 ring. In (2) the bidentate ligand is replaced by two monodentate methylamine ligands of approximately the same donor power, indicating that the Cd–N bonds are approximately the same in the two reactions. The thermodynamic approach to describing the chelate effect considers the equilibrium constant for the reaction: the larger the equilibrium constant, the higher the concentration of the complex.
== See also == Pneumoconiosis – Scarring of the lungs due to inhaling dust over long periods Asbestosis – Pneumoconiosis caused by inhalation and retention of asbestos fibers Health effects arising from the September 11 attacks – Health issues and effects during and after the September 11 attacks Hawks Nest Tunnel disaster – 1930-35 industrial disaster in West Virginia, U.S. Dust pneumonia Frances Perkins Occupational dust exposure
=== Blood reservoir === Because the liver is an expandable organ, large quantities of blood can be stored in its blood vessels. Its normal blood volume, including both that in the hepatic veins and that in the hepatic sinuses, is about 450 milliliters, or almost 10 percent of the body's total blood volume. When high pressure in the right atrium causes backpressure in the liver, the liver expands, and 0.5 to 1 liter of extra blood is occasionally stored in the hepatic veins and sinuses. This occurs especially in cardiac failure with peripheral congestion. Thus, in effect, the liver is a large, expandable, venous organ capable of acting as a valuable blood reservoir in times of excess blood volume and capable of supplying extra blood in times of diminished blood volume.
Sources: en.wikipedia.org
Many different enzyme systems follow non-Michaelis-Menten behavior. A select few examples include kinetics of self-catalytic enzymes, cooperative and allosteric enzymes, interfacial and intracellular enzymes, processive enzymes, and so forth. Some enzymes produce a sigmoid v by [S] plot, which often indicates cooperative binding of substrate to the active site. This means that the binding of one substrate molecule affects the binding of subsequent substrate molecules. This behavior is most common in multimeric enzymes with several interacting active sites. Here, the mechanism of cooperation is similar to that of hemoglobin, with binding of substrate to one active site altering the affinity of the other active sites for substrate molecules. Positive cooperativity occurs when binding of the first substrate molecule increases the affinity of the other active sites for substrate. Negative cooperativity occurs when binding of the first substrate decreases the affinity of the enzyme for other substrate molecules. Allosteric enzymes include mammalian tyrosyl tRNA-synthetase, which shows negative cooperativity, and bacterial aspartate transcarbamoylase and phosphofructokinase which show positive cooperativity. Cooperativity is common and can help regulate the responses of enzymes to changes in the concentrations of their substrates. Positive cooperativity makes enzymes much more sensitive to [S] and their activities can show large changes over a narrow range of substrate concentration. Conversely, negative cooperativity makes enzymes insensitive to small changes in [S].
Bohr's theory was vindicated by the discovery of element 72: Georges Urbain claimed to have discovered it as the rare earth element celtium, but Bury and Bohr had predicted that element 72 could not be a rare earth element and had to be a homologue of zirconium. Dirk Coster and Georg von Hevesy searched for the element in zirconium ores and found element 72, which they named hafnium after Bohr's hometown of Copenhagen (Hafnia in Latin). Urbain's celtium proved to be simply purified lutetium (element 71). Hafnium and rhenium thus became the last stable elements to be discovered. Prompted by Bohr, Wolfgang Pauli took up the problem of electron configurations in 1923. Pauli extended Bohr's scheme to use four quantum numbers, and formulated his exclusion principle which stated that no two electrons could have the same four quantum numbers. This explained the lengths of the periods in the periodic table (2, 8, 18, and 32), which corresponded to the number of electrons that each shell could occupy. In 1925, Friedrich Hund arrived at configurations close to the modern ones. As a result of these advances, periodicity became based on the number of chemically active or valence electrons rather than by the valences of the elements. The Aufbau principle that describes the electron configurations of the elements was first empirically observed by Erwin Madelung in 1926, though the first to publish it was Vladimir Karapetoff in 1930.
Fructilactobacillus sanfranciscensis is a heterofermentative species of lactic acid bacteria which, through the production mainly of lactic and acetic acids, helps give sourdough bread its characteristic taste. It is named after San Francisco, where sourdough was found to contain the variety, though it is dominant in Type I sourdoughs globally. In fact, F. sanfranciscensis has been used in sourdough breads for thousands of years, and is used in 3 million tons of sourdough goods yearly. For commercial use, specific strains of F. sanfranciscensis are grown on defined media, freeze-dried, and shipped to bakeries worldwide.
Sources: en.wikipedia.org
The end of the vaginal canal is blocked off by an endodermal membrane, which separates the opening from the vestibule. In the fifth month, the membrane degenerates but leaves a remnant called the hymen.
The Vermont Army National Guard and Vermont Air National Guard are collectively known as the Vermont National Guard or "Green Mountain Boys". Both units use the original Green Mountain Boys battle flag as their banner.
== Chestnut mimics == Bay horses also have reddish coats, but they have a black mane, tail, legs and other point coloration. The presence of true black points, even if obscured by white markings, means that a horse is not chestnut. Seal brown or dark bay horses are not chestnut but may be confused with a liver chestnut. Those unfamiliar with horse coat color terminology often call most horses "brown". including chestnuts. Brown, which may be difficult to distinguish visually from dark bay, is always accompanied by black points. Liver chestnuts, in particular, are mistakenly called brown or "seal brown". Silver bay horses typically have chocolate- to red-brown bodies with silvered mane, tail, and legs. The flat reddish-brown color and lack of easily identified black points can confuse even knowledgeable horse persons. Silver dapple horses usually hint at black or dark gray pigment at the roots of the mane and tail, and where their silver points end on the legs. Silvers look a bit "off"-chestnut. To further confuse matters, some flaxen chestnuts have silverish streaks in their manes and tails. However, genetic testing can clarify matters.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.